Radiolabelling and preclinical characterisation of [89Zr]Zr-Df-ATG-101 bispecific to PD-L1/4–1BB
European Journal of Nuclear Medicine and Molecular Imaging · 2024
DOI: 10.1007/s00259-024-06742-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Zhipeng Cao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia. Hauptthemen laut MEDLINE: Zirconium, B7-H1 Antigen, Antibodies, Bispecific. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Melbourne.
Abstract (Originalsprache)
Purpose
ATG-101, a bispecific antibody that simultaneously targets the immune checkpoint PD-L1 and the costimulatory receptor 4-1BB, activates exhausted T cells upon PD-L1 crosslinking. Previous studies demonstrated promising anti-tumour efficacy of ATG-101 in preclinical models. Here, we labelled ATG-101 with 89 Zr to confirm its tumour targeting effect and tissue biodistribution in a preclinical model. We also evaluated the use of immuno-PET to study tumour uptake of ATG-101 in vivo.
Methods
ATG-101, anti-PD-L1, and an isotype control were conjugated with p -SCN-Deferoxamine (Df). The Df-conjugated antibodies were radiolabelled with 89 Zr, and their radiochemical purity, immunoreactivity, and serum stability were assessed. We conducted PET/MRI and biodistribution studies on [ 89 Zr]Zr-Df-ATG-101 in BALB/c nude mice bearing PD-L1-expressing MDA-MB-231 breast cancer xenografts for up to 10 days after intravenous administration of [ 89 Zr]Zr-labelled antibodies. The specificity of [ 89 Zr]Zr-Df-ATG-101 was evaluated through a competition study with unlabelled ATG-101 and anti-PD-L1 antibodies.
Results
The Df-conjugation and [ 89 Zr]Zr -radiolabelling did not affect the target binding of ATG-101. Biodistribution and imaging studies demonstrated biological similarity of [ 89 Zr]Zr-Df-ATG-101 and [ 89 Zr]Zr-Df-anti-PD-L1. Tumour uptake of [ 89 Zr]Zr-Df-ATG-101 was clearly visualised using small-animal PET imaging up to 7 days post-injection. Competition studies confirmed the specificity of PD-L1 targeting in vivo. Conclusion [ 89 Zr]Zr-Df-ATG-101 in vivo distribution is dependent on PD-L1 expression in the MDA-MB-231 xenograft model. Immuno-PET with [ 89 Zr]Zr-Df-ATG-101 provides real-time information about ATG-101 distribution and tumour uptake in vivo. Our data support the use of [ 89 Zr]Zr-Df-ATG-101 to assess tumour and tissue uptake of ATG-101.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia.
- School of Cancer Medicine, La Trobe University, Melbourne, Australia.
- Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.
- School of Chemistry - Bio21 Institute, University of Melbourne, Melbourne, Australia.
- Department of Medicine, University of Melbourne, Melbourne, Australia.
- Antengene Biologics Limited, Shanghai, China.
ORCID-Profile: Andrew Mark Scott
Förderung
- University of Melbourne
Zitieren
APA
Cao, Z., Wichmann, C. W., Burvenich, I. J. G., Osellame, L. D., Guo, N., Rigopoulos, A., O'Keefe, G. J., Scott, F. E., Lorensuhewa, N., Lynch, K. P., & Scott, A. M. (2024). Radiolabelling and preclinical characterisation of [89Zr]Zr-Df-ATG-101 bispecific to PD-L1/4–1BB. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06742-6
Vancouver
Cao Z, Wichmann CW, Burvenich IJG, Osellame LD, Guo N, Rigopoulos A, et al. Radiolabelling and preclinical characterisation of [89Zr]Zr-Df-ATG-101 bispecific to PD-L1/4–1BB. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06742-6
BibTeX
@article{Cao2024,
author = {Cao, Zhipeng and Wichmann, Christian Werner and Burvenich, Ingrid Julienne Georgette and Osellame, Laura Danielle and Guo, Nancy and Rigopoulos, Angela and O'Keefe, Graeme Joseph and Scott, Fiona Elizabeth and Lorensuhewa, Nirmal and Lynch, Kevin Patrick and Scott, Andrew Mark},
title = {Radiolabelling and preclinical characterisation of [89Zr]Zr-Df-ATG-101 bispecific to PD-L1/4–1BB},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
doi = {10.1007/s00259-024-06742-6}
}
EUVIMED